Editor’s Note: This might be the most important investing broadcast of the year. Legendary forecaster Porter Stansberry and Jeff Brown expose one of the most important and consequential financial stories in America today.
They say it’s a coordinated, government-backed mobilization that’s funneling trillions of dollars into a tiny handful of companies. For more details, click here. Or read on below to hear from Porter himself…
You won’t want to accept this.
You’ll reject it. Call me crazy for suggesting it.
I don’t care. I’m used to it. That’s what they called me when I predicted the fall of Fannie Mae and Freddie Mac, the bankruptcy of General Motors, the loss of America’s triple-A credit rating… the list goes on and on.
But I don’t let my emotions blind me to reality. No matter how difficult the truth… no matter how uncomfortable the fact… I follow my research to its logical conclusion.
You should too.
But I know most of you won’t – or can’t.
However, if you have any money in the stock market, savings in the bank – and especially if you are responsible for your family’s wealth – you really need to hear me out.
What I’ve discovered took months of investigation… and years of watching this moment build in the background of everyday life.
A powerful force — one almost no one fully understands — is on the verge of tearing through American life and wealth with brutal efficiency.
It won’t be fair. It won’t be gradual. And it won’t spare the unprepared. Hundreds of millions will feel the impact. Some could be devastated. A few others will come out far richer.
Which side you end up on may come down to one thing: how fast you act.
My job is simple: to make sure you land on the right side of what’s coming.
This force, described by Elon Musk as “the most likely cause of World War 3, demands a response. And it’s getting one.
It’s the reason Trump has been raising trillions of dollars from the Middle East…
The reason he forced Zelensky to hand over rights to half of Ukraine’s enormous mineral deposits…
It’s the reason Apple is spending $500 billion to bring their factories back to U.S. soil.
It’s even behind the President’s strange obsession with Greenland.
The threat of this force looms so large that Trump has privately declared it a national emergency… mobilizing public and private capital on a scale we haven’t seen since the Second World War.
In fact, strange as this may sound, what’s unfolding eerily resembles America’s transition to a total war state, 85 years ago.
Back then, key industrial assets were “drafted” to support the war effort. Boeing, GM, Ford, and Caterpillar were called on to produce tanks, fighter planes, and radar.
Today, the President has recruited the likes of Apple’s Tim Cook, Amazon’s Jeff Bezos, Mark Zuckerberg, and OpenAI’s Sam Altman… to tap their vast resources for his own, undeclared national emergency.
Why has he called upon the world’s largest companies and wealthiest men?
As you’ll see, trillions of dollars are rapidly being directed into a concentrated set of companies closely connected to this national emergency.
In this special broadcast, Jeff Brown and I will reveal what this national emergency is and how Trump and his team are reordering the entire economy to prepare for it.
More importantly, we’ll name the two companies most likely to profit.
This new emergency could determine who retires rich — and who gets wiped out, as it forces an epic rotation of capital from one side of the market to the other.
You still have time to prepare – but not much. In a matter of days, an expected announcement from Trump could send capital flooding into the companies we share in the broadcast.
That’s why we’re urging you to watch today.
Good investing,
Porter Stansberry
P.S. This is already underway. Money is rapidly moving. And we believe several popular stocks could be decimated by it. Don’t wait to be engulfed by it – prepare now. Go here.
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
Written by Leo Miller. Originally Published: 1/13/2026.
Quick Look
- Eli Lilly’s strong late-2025 rally has stalled in early 2026 as investors weigh new competitive and strategic developments.
- Novo Nordisk’s launch of an oral weight-loss drug pressured LLY shares, but the reaction may overstate the near-term impact.
- Lilly’s acquisition of Ventyx Biosciences adds optionality through inflammation-focused therapies that could complement its GLP‑1 portfolio.
In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the stock rose 41%. Optimism around Lilly's current and developmental weight-loss and diabetes treatments helped fuel the rally. Lilly also conceded relatively little in a drug-pricing deal with the Trump administration, allowing it to secure tariff exemptions for three years.
As of the Jan. 12 close, Lilly shares were essentially flat for 2026, but the stock has shown notable volatility. Two developments drove that movement: one that markets reacted negatively to, and another that pushed the stock higher. Eli Lilly's top competitor, Novo Nordisk A/S (NYSE: NVO), and a relatively unknown firm, Ventyx Biosciences (NASDAQ: VTYX), have prompted investors to trade the shares up and down.
Novo's "Wegovy Pill" Release Sends LLY Sinking
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)
We've found The Next Elon Musk… and what we believe to be the next Tesla.
It's already racked up $26 billion in government contracts.
Peter Thiel just bet $1 Billion on it.
On Jan. 5, Novo Nordisk said its new "Wegovy Pill" was now available across the United States, becoming the first company to offer an oral weight-loss treatment in the country. That announcement knocked LLY shares down roughly 3.6%, marking Lilly's largest single-day decline of 2026 as investors priced in another competitor on the market.
That reaction may have been a bit overstated. The Food and Drug Administration approved the Wegovy Pill on Dec. 22, 2025, and Novo said at that time it would roll the drug out in the U.S. in "early January 2026." Investors therefore had advance notice the release was imminent, making the size of the Jan. 5 drop somewhat surprising.
Still, the breadth of the initial rollout may have caught some market participants off guard. Novo is making the Wegovy Pill available through more than 70,000 pharmacies right away. Lilly is aiming for approval of its weight-loss pill, orforglipron, "as early as Q2 this year."
LLY Posts Big Gain on Ventyx Deal
On the other side of the ledger, Lilly recorded its largest single-day gain of 2026 on Jan. 7. The Wall Street Journal reported Lilly was in advanced talks to buy Ventyx Biosciences, and LLY shares jumped 4.1%. After the market closed, Lilly confirmed it would acquire Ventyx for $14 per share, or about $1.2 billion. The stock gave back roughly half that gain the next day, falling around 2% on Jan. 8, but the overall market reaction leaned positive.
Acquisitions often produce mixed reactions, so the pickup here is notable. For example, Lilly shares fell 2% on June 17, 2025, after announcing its $1 billion to $1.3 billion purchase of Verve Therapeutics. There appears to be something about Ventyx that investors particularly like.
Ventyx is developing drugs targeting conditions driven by inflammation, which could complement GLP‑1 therapies that also appear to reduce inflammation. Harvard Health Publishing, part of Harvard Medical School, highlighted a Nature Medicine study showing that people taking GLP‑1s experienced a 10% to 20% lower incidence of several chronic diseases, including heart and lung failure—outcomes Harvard linked to reduced inflammation.
In October 2025, Ventyx released Phase 2 results for its drug VTX3232. In part of the study, patients received both VTX3232 and semaglutide (the active ingredient in Novo's Wegovy). The combination produced a "clinically meaningful benefit on inflammation" versus semaglutide alone and showed a "statistically significant reduction in liver inflammation" for patients with ≥5% baseline liver fat.
VTX3232's Potential: A Weight-Loss Drug Add-On?
Those data suggest VTX3232 could be positioned as an add-on to weight-loss treatments to enhance inflammation reduction. If VTX3232 ultimately gained FDA approval, it could create a new revenue stream that leverages Lilly's momentum in weight-loss drugs—likely why investors reacted favorably to the acquisition news. Still, whether VTX3232 or any of Ventyx's other candidates will secure approval remains highly uncertain.
This email communication is a sponsored email from Porter & Company, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you have questions or concerns about your account, please email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Sixth Floor, Sioux Falls, South Dakota 57103. United States of America..
0 التعليقات:
إرسال تعليق